We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Advisory Committee Recommends Approval for Cannabis Derived Treatment for Epilepsy
FDA Advisory Committee Recommends Approval for Cannabis Derived Treatment for Epilepsy
An FDA advisory committee voted unanimously to recommend approval of a drug for Lennox-Gastaut syndrome and Dravet syndrome that, if approved, would be the first FDA-approved cannabis-derived product, GW Pharma’s NDA for a cannabidiol oral solution.